Abstract:
The present invention provides a toric multifocal contact lens having a cylindrical optical power to correct astigmatism vision errors and a multifocal power to compensate for presbyopia. A toric multifocal contact lens of the invention has a central axis, an anterior surface having a first central optical zone, and an opposite posterior surface having a second central optical zone. The first central optical zone and the second central optical zone combine to provide a cylindrical optical power to correct astigmatism vision errors and a multifocal power to compensate for presbyopia.
Abstract:
Ophthalmic lenses for correcting astigmatism having a posterior surface with a central optic zone, a peripheral zone, and a blending zone therebetween. The surface of the central zone may be asphero-toric and the surface of the peripheral zone aspheric, with these flatter slopes smoothening out the transition between the central and peripheral zones. The blending zone gradually transitions the curvatures of the central and peripheral zones to further smoothen out the central-to-peripheral-zone transition.
Abstract:
The present invention provides pharmaceutical formulations comprising a solid ionic complex of a polypeptide having an isoelectric point lower than physiological pH and an anionic carrier molecule. The formulations of the invention are suitable as depot formulations for the sustained release of therapeutic polypeptides.
Abstract:
The present invention provides pharmaceutical formulations characterized by improved stability of the pharmaceutically active compounds contained therein, methods for preparing the same, and methods of use thereof. The pharmaceutical compositions of the present invention comprise a stable water-insoluble complex of a pharmaceutically active compound and a carrier macromolecule. The advantages of the pharmaceutical compositions of the invention include, for example, the increased stability of a pharmaceutically active compound contained therein.
Abstract:
A contact lens or phakic IOC lens is provided with a peripheral portion that has a power profile that provides optical control of peripheral vision images. Typically, the central portion of the lens is also provided with optical control. The power profile of the lens at the boundary of the central and peripheral portions meets certain boundary conditions that ensure that the lens provides a desired or selected vision correction. Because the peripheral portion of the lens provides optical control that defocuses the peripheral vision image relative to the retina, the lens can be used to prevent or inhibit growth of the eye, thereby preventing or inhibiting myopia or the effects of myopia.
Abstract:
This invention is related to contact lenses. In particular, the present invention is related to a toric contact lens design with a plurality thickness zones in the carrier portion of the lens for increased rotational stability.
Abstract:
The present invention provides a series of aspherical contact lenses, each lens having a first central optical zone on its anterior surface and a second central optical zone on its posterior surface. Both central optical zones are aspherical surfaces. The first central optical zone is designed to have a surface which provides a target optical power and an optical power profile selected from the group consisting of (a) a substantially constant optical power profile, (b) a power profile mimicking the optical power profile of a spherical lens with an identical targeted optical power, and (c) a power profile in which lens spherical aberration at 6 mm diameter is from about 0.65 diopter to about 1.8 diopters more negative than spherical aberration at 4 mm diameter.
Abstract:
A lens is provided that is capable of preventing or slowing the progression of myopia when worn by a person. The lens has a power profile that reduces on-axis and off-axis hyperopic defocus created by the optics of the eye by creating on-axis and off-axis myopic defocus. The on-axis and off-axis myopic defocus is created by providing light rays that pass through a central vision region of the optical portion and light rays that pass through a peripheral region of the optical portion an increase in positive (plus) power. The overall effect is to prevent or slow the progression of myopia without any perceptible degradation in the person's central vision.
Abstract:
The present invention provides pharmaceutical formulations comprising a solid ionic complex of a polypeptide having an isoelectric point lower than physiological pH and an anionic carrier molecule. The formulations of the invention are suitable as depot formulations for the sustained release of therapeutic polypeptides.
Abstract:
A contact lens includes a central zone and a peripheral zone. The central zone extends radially from a center to a central intermediate edge and has a radius corresponding to a radius of a contracted pupil of a user when subjected to a high ambient light condition. The central zone also has a constant first refractive power across the central zone. The peripheral zone extends radially from the central intermediate edge to an outer edge and has a radius corresponding to a dilated pupil of the user. The peripheral zone has a refractive power that is equal to the first refractive power at the intermediate edge and that increases radially to a second refractive power, different from the first refractive power, at the outer edge. The contact lens also includes a non-optical zone that extends radially from the outer edge to an outermost radius corresponding to a radius of a user's cornea.